Abbott Gets TriLipix Approval, Ensuring Lipid Lowering Franchise Beyond TriCor
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval bodes positively for Abbott/AstraZeneca’s joint development of a TriLipix/Crestor combination.
You may also be interested in...
Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 19 to consider how cardiovascular outcomes data on fenofibrate use in combination with simvastatin relate to the efficacy and safety of Trilipix, Abbott's second-generation fenofibrate product.
Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 19 to consider how cardiovascular outcomes data on fenofibrate use in combination with simvastatin relate to the efficacy and safety of Trilipix, Abbott's second-generation fenofibrate product.
Abbott, AstraZeneca Riding Crestor Wave With Expanded Partnership
Abbott's deal with AstraZeneca to co-promote Crestor offers a chance for the firms to test drive their marketing relationship well in advance of the potential approval of an experimental combination fenofibrate/statin product they are developing together